Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-08-26
Item 5.02
The filing discloses both the departure of Brady Hayden as CFO and the appointment of Sean Piche as CFO, effective September 1, 2026. While both events occur, the principal focus and substantive disclosure centers on the appointment of Piche, including detailed background (30 years of finance experience, prior roles at EY, NBCUniversal, Viacom), his compensation package ($120,000–$180,000 base salary, 100% bonus, 150,000 RSUs), and his strategic role in the company's next growth phase. The departure is noted as non-contentious and receives minimal elaboration. This is material to investors as CFO transitions affect financial strategy and capital allocation at a company reporting record quarterly results.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-26
Item 5.02
CPI Card Group appointed Brennan Hughes as Chief Accounting Officer effective August 24, 2026. Hughes brings 25+ years of finance and accounting leadership experience, including prior service as Chief Accounting Officer at Janus Henderson Group. The Compensation Committee approved comprehensive compensation arrangements including base salary of $350,000, short-term and long-term incentive targets of $200,000 each, a $100,000 restricted stock unit award, and a $150,000 sign-on bonus.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-26
Item 5.02
The filing discloses the appointment of Erica N. Truban as a director of F&M Bank Corp and its subsidiary Farmers & Merchants Bank, effective August 25, 2026. The principal action is a person taking a governance role. While the disclosure also mentions standard director compensation arrangements, the core event is the appointment itself, which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-08-25
Item 5.02
Renasant Corporation announced the appointment of Catherine Mealor as Chief Financial Officer, effective January 1, 2027, with her joining the company on October 5, 2026 as Executive Vice President. The appointment includes detailed employment terms and compensation arrangements. James C. Mabry IV will retire as CFO effective December 31, 2026, and transition to an executive advisor role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 5.02
Robert A. Garechana was appointed as Chief Financial Officer, Executive Vice President, and Treasurer of Sun Communities, Inc., effective September 8, 2026, succeeding Fernando Castro-Caratini who transitions to an advisory role. The appointment includes a five-year employment agreement with a $625,000 base salary, 150% target bonus, and $2.5 million in restricted stock grants.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 5.02
Chris Fink and Kelly Haecker were appointed to Pure Cycle's board of directors effective August 24, 2026, filling two vacancies and returning the board to eight directors. Both are independent directors with relevant expertise in municipal finance and public company financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-25
Item 5.02
Commonwealth Edison announced multiple executive appointments and promotions effective October 5, 2026 and January 1, 2027, including Jeanne Jones to Executive Vice President of Finance and Strategy, Robert Kleczynski to Chief Financial Officer, Caroline Fulginiti to Vice President and Controller, and Andrew Plenge to ComEd's Chief Financial Officer, as part of a succession plan.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-25
EX-99.1
The press release announces the appointment of Elijah Tyshynski as Chief Financial Officer and his joining the senior leadership team, following Alexander Dann's announced retirement from the CFO role. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a senior officer position. The disclosure emphasizes Tyshynski's extensive financial and capital markets experience and his role in supporting the Company's growth strategy, making this a material executive appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-25
Item 5.02
The filing discloses the appointment of Benjamin J. Branstetter as Chief Financial Officer effective September 1, 2026, succeeding William A. Byers. While the section also includes Brent B. Secrest's appointment as President – Logistics and Transportation and William A. Byers' retirement, the most material and salient event is Branstetter's appointment to the CFO role, a C-suite position critical to financial oversight. The appointment includes compensatory modifications (increased base salary to $600,000 and long-term incentive award of 400% of base salary), underscoring its significance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 8.01
Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer effective August 24, 2026. Dr. Patni brings 25+ years of biopharmaceutical executive experience, including prior roles as CEO and Chief R&D Officer, and a successful track record guiding investigational medicines through regulatory approvals. This appointment is material to the company's clinical development strategy and pipeline advancement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-25
Item 5.02
Michael Guina was appointed Chief Operating Officer effective August 24, 2026, a material executive leadership change. While Matthew Lesmeister's departure from the COO role is also disclosed, the principal action disclosed is Guina's appointment to a C-suite position, making exec_appointment the most salient classification. The filing emphasizes the appointment date and Guina's transition from Chief Commercial Officer, with no additional compensation triggered by the change.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 5.02
Craig L. Tendler, M.D., was appointed as a director of Parabilis Medicines on August 22, 2026, to fill a newly created vacancy on the Board. Dr. Tendler brings over 30 years of oncology drug development experience, including two decades in senior leadership roles at Johnson & Johnson overseeing clinical development and medical affairs.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-25
Item 5.02
The filing discloses the election of Gregory Ciongoli as a Class II director effective immediately, with appointment to the Audit Committee and Nominating and Corporate Governance Committee. While the Item 5.02 also includes the resignation of two directors (Dr. Bennett and Dr. Karabelas), the principal disclosed action centers on the appointment of a new director with specific compensation details ($550,000 initial equity award, annual retainers, and committee assignments). The appointment of a director with substantial board experience and expertise is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 80%
filed 2026-08-25
Item 5.02
Kohl's appointed Arianne Parisi as Senior Executive Vice President and Chief Customer Officer, a newly created role effective September 1, 2026, consolidating responsibility for omnichannel customer experience, marketing, brand, loyalty, and digital commerce under her leadership reporting to CEO Michael J. Bender. The filing also discloses the departure of Christie Raymond as Chief Marketing Officer, effective September 9, 2026.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-25
The 6-K discloses the appointment of Mr. Chan Chee Leong as Independent Director and Chair of Compensation Committee, and Mr. Tan Kwang Leng as Chief Financial Officer, both effective August 24, 2026. While the filing also mentions Mr. Liu Wen Tao's resignation as Independent Director, the principal disclosed action is the two new appointments to material roles (director and CFO), making exec_appointment the primary classification. These are material changes to the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
The filing discloses the appointment of Dr. Mukesh Prasad as a director and member of the audit and compensation committees of Cantor Equity Partners IV, Inc., effective August 25, 2026. Item 5.02(d) explicitly covers "Appointment of Certain Officers" and the prose centers on Dr. Prasad taking a board role with committee assignments. Board appointments are material governance events affecting investor assessment of the company's leadership and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-25
Item 5.02
The filing discloses both the voluntary resignation of CEO Miles Suk (effective August 19, 2026) and the appointment of M. Fatih Karatas as Interim CEO (effective August 25, 2026). While both events are disclosed, the principal action emphasized is the appointment of a new interim CEO with detailed background and qualifications, making exec_appointment the most salient classification. The departure is secondary context to the leadership transition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-25
EX-99.1
Draganfly announced the appointment of Brigadier General AJ Pasagian (Ret'd) as President of Draganfly Defense USA. This is a clear executive appointment of a named officer to a material leadership role overseeing the Company's U.S. defense operations. Pasagian brings 35+ years of military service and prior experience as Commanding General of Marine Corps Systems Command, making this a significant senior leadership appointment that would affect investor assessment of the company's defense-sector strategy and execution capability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 5.02
The filing discloses the appointment of Eugenia Gibbons as Chief Product Officer, effective August 31, 2026. While the disclosure includes compensatory details (base salary of $475,000, sign-on bonus of $250,000, RSUs valued at $8,075,000, and PSUs valued at $1,425,000), the principal disclosed action is the appointment of a named executive to a C-suite role. This is material to investors as it represents a significant leadership change at a public company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-25
Item 5.02
Karl Bollingberg and Kim DeVore were declared elected as member directors to the Federal Home Loan Bank of Des Moines Board for four-year terms commencing January 1, 2027.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-25
Item 5.02
Michelle Buczkowski was appointed Chief Commercial Officer effective August 24, 2026, consolidating sales, business development, government affairs, marketing, and communications under her leadership. Her compensation was increased with a base salary of $440,000 and target short-term incentive of 100% of base.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 5.02
The Board of Directors unanimously elected William J. Turner, Jr. as a Member Director effective August 19, 2026, filling a vacancy on the Board. Turner's compensation arrangement under the 2026 Director Compensation Policy was also disclosed.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-25
The 6-K discloses the appointment of Ms. Yaqing Wei as Chief Executive Officer, Chairperson of the Board, and Director on August 24, 2026, following the resignation of Mr. Xiangyang Wen from those same positions. While both a departure and an appointment occur, the principal disclosed action is the appointment of a new CEO and board chair—a material leadership change. The filing includes Ms. Wei's biography and references an employment agreement (Exhibit 10.1), confirming this is a discrete executive appointment event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-25
EX-99.1
The exhibit announces the appointment of Rupal Hollenbeck to Lightspeed's Board of Directors, effective October 1, 2026. This is a clear governance event involving the addition of a director with significant technology and go-to-market expertise. Although the exhibit also discloses a concurrent board departure (Nathalie Gaveau stepping down), the principal disclosed action is Hollenbeck's appointment to a director role, making exec_appointment the appropriate classification. Board composition changes are material to investors assessing governance quality and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-25
Item 5.02
While the disclosure centers on John Markovich's retirement as CFO effective September 2, 2026, the principal forward-looking action is the appointment of Greg Golkov as acting Chief Financial Officer and principal financial and principal accounting officer. The filing emphasizes Golkov's qualifications (25+ years of finance and accounting experience, prior public company roles at Butterfly Network and Kaseya, CPA credential) and his existing tenure at D-Wave since May 2023. The appointment of a new CFO is material to investors assessing the company's financial leadership and governance continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
The disclosure centers on the appointment of Ash Bhumbla as Executive Vice President and Chief Financial Officer, effective September 8, 2026. While the filing also details comprehensive compensatory arrangements (base salary of $700,000, long-term incentive target of $2.1 million, sign-on awards totaling $1.9 million), the principal disclosed action is the appointment of a named executive to a C-suite role. The compensation details are ancillary to the appointment itself and do not constitute a separate material compensation event independent of the hiring.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-24
Item 5.02
Richard N. Preece was appointed as a director of Jack Henry & Associates on August 20, 2026, to fill a vacancy created by David B. Foss's retirement. The filing details his background as CEO of GoGuardian and prior roles at LegalZoom and Intuit, his committee assignments, and his compensation arrangements. While the filing also mentions Wes Brown's non-reelection due to mandatory retirement age, the principal disclosed action is Preece's appointment to the Board, making this an exec_appointment event. The appointment of a director with significant operational and technology experience to a major S&P 500 company is material to investors.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-24
EX-99.1
The announcement discloses the appointment of Jann Brown to TORM's Board of Directors effective 01 October 2026, following a planned succession process. Additionally, Annette Malm Justad has been promoted to Senior Independent Director. These are discrete governance actions involving the appointment and promotion of directors, which are material to investors assessing board composition and governance strength.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 8.01
Murphy Oil announced the appointment of Michol L. Ecklund as Senior Vice President, Chief Legal Officer and Corporate Secretary, effective August 31, 2026. This is a material executive appointment to a C-suite position reporting directly to the CEO. The disclosure includes her extensive background (25+ years in energy industry, prior roles at Marathon Oil and Callon Petroleum) and her responsibilities overseeing legal, compliance, governance, government affairs, land, sustainability and risk management functions as a member of the Executive Leadership Team.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
Ken West was appointed as President and Chief Operating Officer of QXO, Inc., effective September 1, 2026. West brings 20+ years of operational leadership experience from Honeywell and PPG and will report directly to the CEO with responsibility for day-to-day operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-24
Item 5.02
Philipp Niemann, CEO of Lhoist S.A., was appointed as a director of Martin Marietta effective August 21, 2026, following the Board's increase in size from ten to eleven directors in connection with the Lhoist North America acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-24
Item 5.02
The filing discloses the appointment of Henry Gosebruch to ANI's Board of Directors effective August 19, 2026, with significant compensation details (initial restricted stock award of $525,000). While the filing also mentions Muthusamy Shanmugam's resignation as a director, the principal disclosed action centers on the board appointment of an experienced executive with deep M&A and strategy expertise during a stated "pivotal moment" for the company's transformation. The appointment is material to investors given Gosebruch's track record and the company's strategic positioning.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
Daniel J. Beck was appointed as Chief Financial Officer of USBC, Inc., effective August 27, 2026, with a base salary of $400,000 and a 2.5 million share option grant.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-24
Item 5.02
The filing discloses two executive actions: (1) placement of CFO Daniel E. Bachus on paid administrative leave effective August 21, 2026, in connection with a governmental investigation involving non-employee third-party stock trades, and (2) appointment of Lori Browning as interim CFO and interim principal financial officer effective the same date. While both a departure and appointment occur, the principal disclosed action centers on the appointment of Browning to the CFO role, with her background and qualifications detailed. The departure is contextual to the appointment. The investigation and leave are material to investors as they affect CFO continuity and governance, though the company clarifies it is not a focus of the investigation and the leave does not reflect financial statement or accounting issues.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
The filing discloses that on August 20, 2026, the Board appointed Binson Lau as Co-Chief Executive Officer of Integrated Wellness Acquisition Corp, effective immediately. This is a clear executive appointment of a named officer to a C-suite position. While Lau was already serving as Chairman since February 2024, his elevation to Co-CEO represents a material change in executive leadership and is the principal event disclosed in Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-24
Item 5.02
Samuel J. Poletti was appointed as Chief Financial Officer effective August 24, 2026, succeeding Baris Oran. The appointment includes a base salary of $725,000, performance stock units of $860,000, and international assignment provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-24
Item 5.02
The Board appointed Laurie Bergman as Vice President, Chief Financial Officer and Treasurer effective August 24, 2026, replacing departing CFO Michael Feehan. The appointment is material as it represents a change in senior financial leadership at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
FibroBiologics appointed Leigh Steinberg as a Class II director effective August 20, 2026, to serve until the 2028 annual meeting. Steinberg brings 50+ years of dealmaking experience as a legendary sports agent and has long-standing advocacy for human longevity and chronic disease, areas aligned with the company's fibroblast-based therapeutic pipeline.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
Trex appointed Brian J. Taylor as Senior Vice President and Chief Commercial Officer, a newly created role effective August 24, 2026, with responsibility for sales, marketing, and information technology. The appointment includes a base salary of $480,000, equity grants, signing bonus, and severance arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-24
Item 5.02
The filing discloses both a departure (Justin Trojanowski resigning as Principal Financial Officer effective September 1, 2026) and an appointment (Nicholas Rossettos appointed as Chief Financial Officer and Principal Financial and Accounting Officer effective the same date). While both events occur, the principal disclosed action centers on the appointment of Rossettos to the critical CFO/Principal Accounting Officer role, with detailed background on his 30+ years of experience in biopharmaceutical finance. The appointment of a new CFO is material to investors assessing financial leadership and reporting integrity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
David Denker was appointed Chief Operating Officer of Rocky Mountain Chocolate Factory, effective August 14, 2026, approved by the Board on August 18, 2026. Denker was promoted from Vice President of Franchise Development to this senior leadership role with expanded responsibility for manufacturing, franchise operations, and strategic execution. The appointment includes a base salary of $185,000, a bonus target of 50%, and equity grants.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 5.02
Todd Edwards was appointed as Chief Commercial Officer of Oruka Therapeutics, commencing August 24, 2026, pursuant to a letter agreement dated July 22, 2026. The disclosure details his appointment, compensation package (base salary of $525,000, 40% bonus target, stock options and RSUs), and severance arrangements. This is a material executive appointment of a senior officer with significant commercial responsibility at a biopharmaceutical company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-24
Item 5.02
W. Noah Springer was appointed as Chief Executive Officer effective January 1, 2027, following a board-approved succession plan, and was elected to the board of directors. This appointment represents a significant leadership transition at the major REIT.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
Item 7.01
Proto Labs announced the appointment of Sam Ramahi as Chief Operations Officer, effective August 31, 2026. The disclosure centers on a named executive taking a new role—a C-suite position with significant operational responsibilities. This is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership and operational direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-24
EX-99.1
The exhibit discloses the appointment of Dr. Mahan Chehrenama, DO, as Chief Medical Officer of BetterLife Pharma in August 2026. This is a material executive appointment to a senior leadership role leading clinical development of the company's lead asset BETR-001 toward an anticipated IND application in Q1 2027. While the disclosure also includes a stock option grant (500,000 shares at $0.285), the principal disclosed action is the appointment itself, making exec_appointment the primary classification. The appointment is material because it brings specialized migraine drug-development expertise to a critical stage of the company's lead program.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-24
EX-99.1
The exhibit announces the appointment of Nicole Rusaw, CPA, CA, as Chief Financial Officer of PowerBank Corporation, effective immediately, succeeding Sam Sun. This is a clear executive appointment of a named officer to a C-suite role. The disclosure emphasizes her 20+ years of public company finance leadership and her expected contributions to the company's financial strategy and growth, making it material to investors' assessment of the company's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-24
The filing discloses the appointment of two new independent directors, Jim Ahern and Menachem Shalom, to Polar Power's Board on August 17, 2026. Item 5.02 explicitly covers this appointment event. The disclosure is material because board composition changes affect governance and strategic direction, particularly given the company's stated focus on defense market expansion and restructuring strategy. The appointment of Shalom was designated by Mayers Ventures LLC under a convertible note agreement, adding a capital structure dimension to the governance change.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-24
Item 5.02
Dr. Martin D. Madaus was appointed as Interim President and CEO on August 22, 2026, following the resignation of John P. Marotta. Madaus brings significant industry experience as a former CEO of Millipore, Ortho Clinical Diagnostics, and Roche Diagnostics North America.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-08-24
EX-99.2
Gogoro appointed Jacky Lee as Principal Financial Officer effective August 21, 2026, succeeding CFO Bruce Aitken who is retiring effective September 1, 2026. Lee brings relevant financial and operational experience to the role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-24
Item 5.02
Kevin Sellers was appointed as Chief Executive Officer and Board member effective August 24, 2026, following Joseph Hammer's resignation from the CEO role. Sellers' appointment includes an employment agreement with base salary, bonus, and RSU grant as the company undergoes strategic expansion into oil and gas.
View raw filing on EDGAR →